New drug combo targets silent liver threat in diabetics
NCT ID NCT07303803
Summary
This study is testing whether a new drug called chiglitazar, when taken with standard liver-protective vitamins, can help people who have both a serious fatty liver disease (MASH) and type 2 diabetes. It will involve 300 adults and compare the drug to a placebo over 78 weeks. The main goal is to see if the treatment can reduce liver inflammation and prevent existing scarring from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ditan Hospital of integrated traditional Chinese and Western Medicine Center
Beijing, Beijing Municipality, 100015, China
-
Renji hospital of Shanghai Jiao Tong University School of Medical
Shanghai, Shanghai Municipality, 200001, China
-
Ruijin Hospital of Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200020, China
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, 200083, China
-
Shanghai Punan Hospital of Pudong New District (Punan Branch of Renji Hospital, Shanghai Jiaotong University School of Medicine)
Shanghai, Shanghai Municipality, 200125, China
-
Southern Hospital
Guangzhou, Guangdong, 510515, China
-
Southwest Hospital of Third Military Medical University
Chongqing, Chongqing Municipality, 400038, China
-
Taihe Hospital
Shiyan, Hubei, 442000, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350005, China
-
The First Affiliated Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, 710061, China
-
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The First Teaching Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054, China
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510000, China
-
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, 300192, China
-
Wuhan Union Hospital of Huazhong University of Science and Technology
Wuhan, Hebei, 430022, China
-
Xiangya hospital of Central South University
Changsha, Hunan, 410008, China
Conditions
Explore the condition pages connected to this study.